← Back to patent-cliff list
ACD-440
Tier C — Watch / tradeACD-440
Alzecure Pharma Ab
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TRPV1
Indications (approved)：神经痛, Pain
Regional status
US
-
EU
Phase II
2022-05-25
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ACD-440?
Approved indications include: 神经痛, Pain.
When does the ACD-440 patent expire?
No public expiry year is available for ACD-440 yet; this page updates once verified.
How do I get a quote for ACD-440 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05